Rhythm Pharmaceuticals (BMV:RYTM *) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

RYTM * Aperçu des actions

A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.

RYTM * analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	5/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Récompenses

Se négocie à 77.8% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 65.5% par an

Analyse des risques

Les actions sont très illiquides

Les actionnaires ont été dilués au cours de l'année écoulée

Rhythm Pharmaceuticals, Inc. Concurrents

Protagonist Therapeutics

NasdaqGM:PTGX

US$2.8b

TG Therapeutics

NasdaqCM:TGTX

US$3.3b

Telix Pharmaceuticals

ASX:TLX

AU$7.3b

Sinocelltech Group

SHSE:688520

CN¥17.0b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Rhythm Pharmaceuticals
Historique des cours de bourse
Prix actuel de l'action	US$680.21
Plus haut sur 52 semaines	US$733.48
Plus bas sur 52 semaines	US$427.50
Bêta	2.04
1Variation sur 1 mois	0%
Variation sur 3 mois	n/a
Variation sur 1 an	n/a
3Variation sur 3 ans	65.90%
Variation sur 5 ans	59.00%
Évolution depuis l'introduction en bourse	59.00%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	RYTM *	MX Biotechs	MX Marché
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement vs Industrie: Données insuffisantes pour déterminer la performance de RYTM * par rapport au secteur MX Biotechs.

Rendement vs marché: Données insuffisantes pour déterminer la performance de RYTM * par rapport au marché MX.

Volatilité des prix

Is RYTM *'s price volatile compared to industry and market?
RYTM * volatility
RYTM * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Cours de l'action stable: RYTM * n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de RYTM * au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2008	226	David Meeker	rhythmtx.com

Rhythm Pharmaceuticals, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Rhythm Pharmaceuticals se comparent-ils à sa capitalisation boursière ?
RYTM * statistiques fondamentales
Capitalisation boursière	Mex$54.65b
Bénéfices(TTM)	-Mex$4.95b
Recettes(TTM)	Mex$1.66b

32.9x

Ratio P/S

-11.0x

Ratio P/E

Le site RYTM * est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
RYTM * compte de résultat (TTM)
Recettes	US$91.93m
Coût des recettes	US$10.69m
Marge brute	US$81.24m
Autres dépenses	US$355.11m
Les revenus	-US$273.87m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-4.49
Marge brute	88.37%
Marge bénéficiaire nette	-297.93%
Ratio dettes/capitaux propres	174.4%

Quelles ont été les performances à long terme de RYTM *?

Voir les performances historiques et les comparaisons

RYTM * Aperçu des actions

Récompenses

Analyse des risques

Rhythm Pharmaceuticals, Inc. Concurrents

NasdaqGM:PTGX

US$2.8b

NasdaqCM:TGTX

US$3.3b

ASX:TLX

AU$7.3b

SHSE:688520

CN¥17.0b

Historique des prix et performances

Nouvelles et mises à jour récentes

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Recent updates

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Forecast to breakeven in 2026

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022)

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide)

Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021)

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment

Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder

High number of new directors

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes

Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise